Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 13, Pages 1302-1308
Publisher
American Society of Clinical Oncology (ASCO)
Online
2014-03-18
DOI
10.1200/jco.2013.51.4489
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
- (2014) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
- (2013) R. Wendel Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Update of randomized trials in recurrent disease
- (2011) E. Pujade-Lauraine et al. ANNALS OF ONCOLOGY
- Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
- (2011) A. Lortholary et al. ANNALS OF ONCOLOGY
- Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer
- (2011) Kathryn F. McGonigle et al. CANCER
- Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
- (2011) R. Wendel Naumann et al. DRUGS
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
- (2010) D.L. Richardson et al. GYNECOLOGIC ONCOLOGY
- Clinical predictors of bevacizumab-associated gastrointestinal perforation
- (2010) Janos L. Tanyi et al. GYNECOLOGIC ONCOLOGY
- Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
- (2009) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
- (2009) S. Kobold et al. ONCOLOGIST
- Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
- (2008) Jalid Sehouli et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now